EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The impact of COVID‐19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database

Yasutsugu Akasaki, Takenori Inomata iD, Masao Iwagami, Jaemyoung Sung, Ken Nagino iD, Takeya Adachi, Hideaki Morita, Mayumi Tamari, Keigo Kainuma, Keiko Kan-O, Hiroaki Ogata, Masafumi Sakashita und 16 weitere

Clinical and Translational Allergy · 2024-09 · 14 (9)

DOI: 10.1002/clt2.12394 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Translational Allergy, online erschienen am 17.09.2024. Verfasst von Yasutsugu Akasaki und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health, Labor and Welfare Sciences Research Grant, Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care, The Institute for Environmental & Gender-specific Medicine, Juntendo University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hay fever (HF) presents with various symptoms, including allergic conjunctivitis and rhinitis, and requires cross‐organ treatment. This study assessed the impact of the coronavirus disease 2019 (COVID‐19) pandemic on HF treatment trends.

Methods

This retrospective cohort study utilized data from the JMDC database collected between January 2018 and May 2021. Patients with HF were identified based on the relevant International Classification of Diseases 10th Revision diagnosis codes and the prescription of HF‐related medications. The treatment approaches were compared during the cedar and cypress pollen allergy season (January to May in Japan) before and during the COVID‐19 pandemic (2018 and 2019, and 2020 and 2021, respectively).

Results

This study included 2,598,178 patients with HF. The numbers of prescribed HF‐related claims in 2018, 2019, 2020, and 2021 were 3,332,854, 3,534,198, 2,774,380, and 2,786,681 times, respectively. Oral second‐generation antihistamine prescriptions decreased by >10% from 2019 to 2020, with a 10% from 2019 to 2020 but increased by >10% from 2020 to 2021. Compared with 2018, 2019, and 2020, the number of claims in the rhinitis symptoms dominant group was significantly decreased in 2021 ( p < 0.001, all). In contrast, the number of claims in the eye symptoms dominant group and the rhinitis and eye symptoms dominant group increased in 2021 compared with that in 2018, 2019, and 2020 ( p < 0.001, all).

Conclusion

Changes in HF treatment and related outcomes could be attributed to lifestyle modifications resulting from the COVID‐19 pandemic. Measures, such as limiting outdoor activities and adopting mask‐wearing practices may have influenced HF symptoms, preventive behaviors, and the overall approach to treating HF.

Schlagwörter

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2allergic conjunctivitisallergic rhinitishay fever

Autor:innen und Institutionen

  • Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • ENGAGE-Task Force, Tokyo, Japan.
  • Department of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Telemedicine and Mobile Health, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • AI Incubation Farm, Juntendo University Graduate School of Medicine, Tokyo, Japan.

ORCID-Profile: Takenori Inomata, Ken Nagino, Sakura Sato

Förderung

  • Health, Labor and Welfare Sciences Research Grant
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
  • The Institute for Environmental & Gender-specific Medicine, Juntendo University
  • Over-the-counter Drug Self-Medication Promotion Foundation
  • The Kondou Kinen Medical Foundation
  • Nishikawa Medical Foundation
  • Japan Agency for Medical Research and Development

Zitieren

APA

Akasaki, Y., Inomata, T., Iwagami, M., Sung, J., Nagino, K., Adachi, T., Morita, H., Tamari, M., Kainuma, K., Kan-O, K., Ogata, H., Sakashita, M., Futamura, M., Kurashima, Y., Nakajima, S., Masaki, K., Ogawa, Y., Sato, S., Miyagawa, A., …, & Nakao, S. (2024). The impact of COVID‐19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database. Clinical and Translational Allergy, 14(9). https://doi.org/10.1002/clt2.12394

Vancouver

Akasaki Y, Inomata T, Iwagami M, Sung J, Nagino K, Adachi T, et al. The impact of COVID‐19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database. Clinical and Translational Allergy. 2024;14(9). doi:10.1002/clt2.12394

BibTeX
@article{Akasaki2024,
  author = {Akasaki, Yasutsugu and Inomata, Takenori and Iwagami, Masao and Sung, Jaemyoung and Nagino, Ken and Adachi, Takeya and Morita, Hideaki and Tamari, Mayumi and Kainuma, Keigo and Kan-O, Keiko and Ogata, Hiroaki and Sakashita, Masafumi and Futamura, Masaki and Kurashima, Yosuke and Nakajima, Saeko and Masaki, Katsunori and Ogawa, Yasushi and Sato, Sakura and Miyagawa, Akihiro and Midorikawa-Inomata, Akie and Fujimoto, Keiichi and Okumura, Yuichi and Fujio, Kenta and Huang, Tianxiang and Hirosawa, Kunihiko and Morooka, Yuki and Murakami, Akira and Nakao, Shintaro},
  title = {The impact of COVID‐19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database},
  journal = {Clinical and Translational Allergy},
  year = {2024},
  volume = {14},
  number = {9},
  doi = {10.1002/clt2.12394}
}
Kostenlos starten →